CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of renal cell carcinoma.
  
  LEARNING OBJECTIVES

  • Evaluate recently presented data with adjuvant anti-PD-1/PD-L1 antibody therapy for patients with RCC at high risk for recurrence after nephrectomy, and consider the current role of this treatment strategy.
  • Appraise available clinical trial data evaluating anti-PD-1/PD-L1 antibody/multikinase inhibitor combinations for previously untreated metastatic RCC (mRCC), and counsel patients regarding the risks and benefits of these novel regimens.
  • Review the biological rationale underlying the investigation of anti-PD-1/anti-CTLA-4 combination therapy as first-line treatment for patients with mRCC, and appreciate long-term research findings documenting the effectiveness of this approach.
  • Assess recently presented clinical trial results with anti-PD-1/PD-L1 antibodies administered as a subcutaneous injection for patients with mRCC, and reflect on the potential benefits of this therapeutic strategy.
  • Understand the biological rationale for exploiting HIF-2α in patients with von Hippel-Lindau-associated and sporadic RCC, and consider the current role of available inhibitors.
  • Develop a rational therapeutic approach to the sequencing of systemic therapies for patients with advanced RCC that progresses on first-line treatment, incorporating multikinase inhibitors, HIF-2α inhibitors, immunotherapeutic agents and other strategies.
  • Appreciate published research findings evaluating the use of available and investigational agents for patients with non-clear cell RCC, and consider the applicability of these strategies in clinical care.
  • Recall available and emerging data with other novel and investigational agents and strategies in testing for RCC, and as applicable, refer eligible patients for clinical trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Thomas E Hutson, DO, PharmD, PhD
  Director
  UMC Cancer Center
  Division Chief, Hematology and Medical Oncology
  Professor of Medicine
  CH Endowed Chair
  Texas Tech University Health Sciences Center School of Medicine
  Lubbock, Texas
  
  Advisory Committees, Consulting Agreements, Contracted Research and Speakers Bureaus: Astellas, AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Exelixis Inc, Merck, Pfizer Inc, Seagen Inc.
  
  Rana R McKay, MD
  Professor of Medicine and Urology
  Associate Director, Clinical Research
  Co-Lead, Genitourinary Program
  Moores Cancer Center
  University of California San Diego
  San Diego, California
  
  Advisor/Consultant: Ambrx, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Exelixis Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Myovant Sciences, Neomorph, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Institutional Research Funding: ArteraAI, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Exelixis Inc, Oncternal Therapeutics, Tempus.
  
  Tian Zhang, MD, MHS
  Associate Professor
  Director of Clinical Research
  Division of Hematology and Oncology
  Department of Internal Medicine
  UT Southwestern Medical Center
  Associate Director for Clinical Research
  Simmons Comprehensive Cancer Center
  Dallas, Texas
  
  Advisory Committees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Gilead Sciences Inc, Janssen Biotech Inc, Lilly, Merck, Novartis, Pfizer Inc, Sanofi; Consulting Agreements: Aptitude Health, DAVA Oncology, Pfizer Inc, Vaniam Group; Contracted Research: ALX Oncology, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, Janux Therapeutics, Lilly, Merck, OncoC4, Pfizer Inc, Tempus; Nonrelevant Financial Relationships: Mashup Media LLC, MJH Life Sciences, PeerView.
  
  MODERATOR
  Sumanta Kumar Pal, MD
  Professor and Vice Chair of Academic Affairs
  Department of Medical Oncology
  City of Hope Comprehensive Cancer Center
  Duarte, California
  
  Travel Support: CRISPR Therapeutics, EverImmune, Exelixis Inc, Ipsen Biopharmaceuticals Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Bristol Myers Squibb, Eisai Inc, and Exelixis Inc.
  
  Release date: March 2025
  Expiration date: March 2026